- Home
- MCRB vs PAVS Comparison
MCRB vs PAVS Comparison
Compare MCRB & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- PAVS
- Stock Information
- Founded
- MCRB 2010
- PAVS 2004
- Country
- MCRB United States
- PAVS United States
- Employees
- MCRB N/A
- PAVS N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- MCRB Health Care
- PAVS Health Care
- Exchange
- MCRB Nasdaq
- PAVS Nasdaq
- Market Cap
- MCRB 81.2M
- PAVS 89.6M
- IPO Year
- MCRB 2015
- PAVS 2019
- Fundamental
- Price
- MCRB $7.06
- PAVS $1.03
- Analyst Decision
- MCRB Hold
- PAVS
- Analyst Count
- MCRB 5
- PAVS 0
- Target Price
- MCRB $73.67
- PAVS N/A
- AVG Volume (30 Days)
- MCRB 146.8K
- PAVS 26.8K
- Earning Date
- MCRB 05-07-2025
- PAVS 01-01-0001
- Dividend Yield
- MCRB N/A
- PAVS N/A
- EPS Growth
- MCRB N/A
- PAVS N/A
- EPS
- MCRB 0.03
- PAVS N/A
- Revenue
- MCRB N/A
- PAVS $6,613,273.00
- Revenue This Year
- MCRB N/A
- PAVS N/A
- Revenue Next Year
- MCRB N/A
- PAVS N/A
- P/E Ratio
- MCRB $213.09
- PAVS N/A
- Revenue Growth
- MCRB N/A
- PAVS 2.50
- 52 Week Low
- MCRB $7.18
- PAVS $0.32
- 52 Week High
- MCRB $30.60
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- MCRB 33.07
- PAVS 17.87
- Support Level
- MCRB $8.92
- PAVS $1.22
- Resistance Level
- MCRB $9.97
- PAVS $1.40
- Average True Range (ATR)
- MCRB 1.08
- PAVS 0.06
- MACD
- MCRB -0.06
- PAVS -0.03
- Stochastic Oscillator
- MCRB 10.61
- PAVS 6.40
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.